| Shehzad Jaffer Bandhani, MD | |
|
3366 Nw Expressway Ste 550, Oklahoma City, OK 73112-4489 | |
| (405) 942-5442 | |
| (405) 942-6448 |
| Full Name | Shehzad Jaffer Bandhani |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 21 Years |
| Location | 3366 Nw Expressway Ste 550, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295005072 | NPI | - | NPPES |
| 200456950A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 29134 (Oklahoma) | Primary |
| 208M00000X | Hospitalist | 29134 (Oklahoma) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Integris Baptist Medical Center, Inc | Oklahoma city, OK | Hospital |
| Integris Southwest Medical Center | Oklahoma city, OK | Hospital |
| Integris Canadian Valley Hospital | Yukon, OK | Hospital |
| Integris Health Edmond | Edmond, OK | Hospital |
| Stillwater Medical Center | Stillwater, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kidney Specialists Of Central Oklahoma, Pc | 7618904988 | 17 |
| Oklahoma Hospital Medicine Physicians Llc | 9830510023 | 110 |
News Archive
GlySens Incorporated announced today that it has secured FDA approval for extending the current human clinical evaluation of its fully implantable continuous glucose monitoring system (the ICGM System) from the originally approved six-month duration to the system's commercially-intended operational duration of twelve months.
Ocean acidification may be impacting upon the population dynamics of marine species and hindering their ability to genetically adapt to future climate change.
The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) applauds the new licensing agreement between the Medicines Patent Pool (MPP) and Gilead Sciences, Inc. to improve access to tenofovir alafenamide fumarate (TAF), a promising new HIV medication.
A prescribing guideline tailored to patients' specific needs reduced the number of opioid pills prescribed after major surgery with researchers reporting a greater than 90 percent patient satisfaction rate with pain management and the highest compliance rate to date with appropriate disposal of leftover pills.
› Verified 8 days ago
| Entity Name | Oklahoma Nephrology Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407803380 PECOS PAC ID: 7012998453 Enrollment ID: O20040601000296 |
News Archive
GlySens Incorporated announced today that it has secured FDA approval for extending the current human clinical evaluation of its fully implantable continuous glucose monitoring system (the ICGM System) from the originally approved six-month duration to the system's commercially-intended operational duration of twelve months.
Ocean acidification may be impacting upon the population dynamics of marine species and hindering their ability to genetically adapt to future climate change.
The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) applauds the new licensing agreement between the Medicines Patent Pool (MPP) and Gilead Sciences, Inc. to improve access to tenofovir alafenamide fumarate (TAF), a promising new HIV medication.
A prescribing guideline tailored to patients' specific needs reduced the number of opioid pills prescribed after major surgery with researchers reporting a greater than 90 percent patient satisfaction rate with pain management and the highest compliance rate to date with appropriate disposal of leftover pills.
› Verified 8 days ago
| Entity Name | Integris Ambulatory Care Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750333936 PECOS PAC ID: 2365408465 Enrollment ID: O20041209000354 |
News Archive
GlySens Incorporated announced today that it has secured FDA approval for extending the current human clinical evaluation of its fully implantable continuous glucose monitoring system (the ICGM System) from the originally approved six-month duration to the system's commercially-intended operational duration of twelve months.
Ocean acidification may be impacting upon the population dynamics of marine species and hindering their ability to genetically adapt to future climate change.
The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) applauds the new licensing agreement between the Medicines Patent Pool (MPP) and Gilead Sciences, Inc. to improve access to tenofovir alafenamide fumarate (TAF), a promising new HIV medication.
A prescribing guideline tailored to patients' specific needs reduced the number of opioid pills prescribed after major surgery with researchers reporting a greater than 90 percent patient satisfaction rate with pain management and the highest compliance rate to date with appropriate disposal of leftover pills.
› Verified 8 days ago
| Entity Name | Kidney Specialists Of Central Oklahoma, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710918420 PECOS PAC ID: 7618904988 Enrollment ID: O20050719000901 |
News Archive
GlySens Incorporated announced today that it has secured FDA approval for extending the current human clinical evaluation of its fully implantable continuous glucose monitoring system (the ICGM System) from the originally approved six-month duration to the system's commercially-intended operational duration of twelve months.
Ocean acidification may be impacting upon the population dynamics of marine species and hindering their ability to genetically adapt to future climate change.
The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) applauds the new licensing agreement between the Medicines Patent Pool (MPP) and Gilead Sciences, Inc. to improve access to tenofovir alafenamide fumarate (TAF), a promising new HIV medication.
A prescribing guideline tailored to patients' specific needs reduced the number of opioid pills prescribed after major surgery with researchers reporting a greater than 90 percent patient satisfaction rate with pain management and the highest compliance rate to date with appropriate disposal of leftover pills.
› Verified 8 days ago
| Entity Name | Mercy Clinic Oklahoma Communities |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386874550 PECOS PAC ID: 1153468921 Enrollment ID: O20091027000755 |
News Archive
GlySens Incorporated announced today that it has secured FDA approval for extending the current human clinical evaluation of its fully implantable continuous glucose monitoring system (the ICGM System) from the originally approved six-month duration to the system's commercially-intended operational duration of twelve months.
Ocean acidification may be impacting upon the population dynamics of marine species and hindering their ability to genetically adapt to future climate change.
The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) applauds the new licensing agreement between the Medicines Patent Pool (MPP) and Gilead Sciences, Inc. to improve access to tenofovir alafenamide fumarate (TAF), a promising new HIV medication.
A prescribing guideline tailored to patients' specific needs reduced the number of opioid pills prescribed after major surgery with researchers reporting a greater than 90 percent patient satisfaction rate with pain management and the highest compliance rate to date with appropriate disposal of leftover pills.
› Verified 8 days ago
| Entity Name | Optimum Care Hospitalist Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306396577 PECOS PAC ID: 3779862446 Enrollment ID: O20161121001476 |
News Archive
GlySens Incorporated announced today that it has secured FDA approval for extending the current human clinical evaluation of its fully implantable continuous glucose monitoring system (the ICGM System) from the originally approved six-month duration to the system's commercially-intended operational duration of twelve months.
Ocean acidification may be impacting upon the population dynamics of marine species and hindering their ability to genetically adapt to future climate change.
The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) applauds the new licensing agreement between the Medicines Patent Pool (MPP) and Gilead Sciences, Inc. to improve access to tenofovir alafenamide fumarate (TAF), a promising new HIV medication.
A prescribing guideline tailored to patients' specific needs reduced the number of opioid pills prescribed after major surgery with researchers reporting a greater than 90 percent patient satisfaction rate with pain management and the highest compliance rate to date with appropriate disposal of leftover pills.
› Verified 8 days ago
| Entity Name | Oklahoma Hospital Medicine Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871113761 PECOS PAC ID: 9830510023 Enrollment ID: O20200526000785 |
News Archive
GlySens Incorporated announced today that it has secured FDA approval for extending the current human clinical evaluation of its fully implantable continuous glucose monitoring system (the ICGM System) from the originally approved six-month duration to the system's commercially-intended operational duration of twelve months.
Ocean acidification may be impacting upon the population dynamics of marine species and hindering their ability to genetically adapt to future climate change.
The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) applauds the new licensing agreement between the Medicines Patent Pool (MPP) and Gilead Sciences, Inc. to improve access to tenofovir alafenamide fumarate (TAF), a promising new HIV medication.
A prescribing guideline tailored to patients' specific needs reduced the number of opioid pills prescribed after major surgery with researchers reporting a greater than 90 percent patient satisfaction rate with pain management and the highest compliance rate to date with appropriate disposal of leftover pills.
› Verified 8 days ago
| Entity Name | Optimum Complete Care, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295359248 PECOS PAC ID: 3678996014 Enrollment ID: O20200702000164 |
News Archive
GlySens Incorporated announced today that it has secured FDA approval for extending the current human clinical evaluation of its fully implantable continuous glucose monitoring system (the ICGM System) from the originally approved six-month duration to the system's commercially-intended operational duration of twelve months.
Ocean acidification may be impacting upon the population dynamics of marine species and hindering their ability to genetically adapt to future climate change.
The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) applauds the new licensing agreement between the Medicines Patent Pool (MPP) and Gilead Sciences, Inc. to improve access to tenofovir alafenamide fumarate (TAF), a promising new HIV medication.
A prescribing guideline tailored to patients' specific needs reduced the number of opioid pills prescribed after major surgery with researchers reporting a greater than 90 percent patient satisfaction rate with pain management and the highest compliance rate to date with appropriate disposal of leftover pills.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shehzad Jaffer Bandhani, MD 3366 Nw Expressway Ste 550, Oklahoma City, OK 73112-4489 Ph: (405) 942-5442 | Shehzad Jaffer Bandhani, MD 3366 Nw Expressway Ste 550, Oklahoma City, OK 73112-4489 Ph: (405) 942-5442 |
News Archive
GlySens Incorporated announced today that it has secured FDA approval for extending the current human clinical evaluation of its fully implantable continuous glucose monitoring system (the ICGM System) from the originally approved six-month duration to the system's commercially-intended operational duration of twelve months.
Ocean acidification may be impacting upon the population dynamics of marine species and hindering their ability to genetically adapt to future climate change.
The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) applauds the new licensing agreement between the Medicines Patent Pool (MPP) and Gilead Sciences, Inc. to improve access to tenofovir alafenamide fumarate (TAF), a promising new HIV medication.
A prescribing guideline tailored to patients' specific needs reduced the number of opioid pills prescribed after major surgery with researchers reporting a greater than 90 percent patient satisfaction rate with pain management and the highest compliance rate to date with appropriate disposal of leftover pills.
› Verified 8 days ago
Evelyn Lorents, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 920 Sl Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-5963 | |
Patrick Bronson Reeves, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 3366 Nw Expressway Ste 550, Oklahoma City, OK 73112 Phone: 405-942-5442 Fax: 405-942-6448 | |
Dr. Jake Lee Evans, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 800 Stanton L Young Blvd, Aat 6300, Oklahoma City, OK 73104 Phone: 405-271-5963 | |
Metri Haddaden, MD Nephrology Medicare: Medicare Enrolled Practice Location: 800 Stanton L Young Blvd # 8425, Oklahoma City, OK 73104 Phone: 405-271-6173 Fax: 410-554-2184 | |
Divya Sharma Divyadarshini, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 800 Stanton L Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-5963 | |
Dr. Philip Barton Miner, Jr., M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 1000 N Lincoln Blvd, Suite 210, Oklahoma City, OK 73104 Phone: 405-271-4644 Fax: 405-271-3296 | |
Gary Lee Worcester, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 3433 Nw 56th St, Ste 400, Oklahoma City, OK 73112 Phone: 405-947-3341 |